Form 4: AbbVie Director Acquires Stock Equivalent Units

AbbVie Inc. Director Edward J. Rapp acquired 145 stock equivalent units, increasing his beneficial ownership to 28,152 units.

Summary

• Edward J. Rapp, a Director of AbbVie Inc., acquired 145 stock equivalent units on September 30, 2025.
• These units were credited as director fees to a stock equivalent unit account under a grantor trust.
• The stock equivalent units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if the fees were invested in AbbVie stock.
• The acquisition price per unit was $231.54.
• Following this transaction, Rapp's total beneficial ownership of stock equivalent units is 28,152.
• The reported balance of units includes those acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The acquisition of stock equivalent units by a director, even as part of compensation, generally signals confidence in the company's long-term prospects and aligns management interests with shareholders. This is a mildly positive indicator.

Positives

• Director Edward J. Rapp increased his beneficial ownership in AbbVie Inc. by acquiring 145 stock equivalent units.
• The acquisition of stock equivalent units aligns the director's financial interests with those of shareholders, as these units earn the same return as AbbVie stock.
• The inclusion of a dividend reinvestment feature for stock equivalent units indicates a long-term investment perspective by the director.

Risks

• The value of the stock equivalent units is directly tied to AbbVie's common stock performance, exposing the holder to market fluctuations and potential loss of value.

Future Outlook

This filing reports a past insider transaction and does not contain any forward-looking statements or guidance from the company.

Industry Context

This Form 4 filing details an individual director's equity transaction, which is a routine regulatory disclosure. While not providing broad industry trends, insider acquisitions, even as part of compensation, can be interpreted as a sign of confidence in the company's future within its competitive pharmaceutical and biotechnology industry.

Related Party Transactions

• Director fees were credited to a stock equivalent unit account under a grantor trust, representing compensation to a related party (a director).

Stakeholder Impact

• Shareholders: The director's increased beneficial ownership aligns his interests with shareholders, potentially signaling confidence in the company's future performance.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this specific filing.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of stock equivalent units by a director as part of compensation. While insider buying can be a positive signal, the relatively small number of units (145) in the context of a large company like AbbVie Inc. and its nature as compensation rather than an open market purchase, does not provide sufficient new information to warrant a change in investment recommendation. It reinforces a 'hold' position, assuming the investor already has a view on ABBV based on its fundamentals.

Keywords

AbbVie, ABBV, Form 4, Insider Transaction, Director, Stock Equivalent Units, Beneficial Ownership, Equity Acquisition, Edward J. Rapp, Pharmaceuticals, Biotechnology